JP2965633B2 - フォシノプリル錠剤 - Google Patents

フォシノプリル錠剤

Info

Publication number: JP2965633B2
Authority: JP; Japan
Prior art keywords: weight; sodium; lactose; povidone; tablet according
Prior art date: 1989-07-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP2185179A

Other languages

English (en)

Japanese (ja)

Other versions

JPH0348623A (ja

Inventor

ロバート・エル・ジェルツェウスキ

トーマス・エム・ウォン

ルイス・ジェイ・グリツィエウィッツ

ネミチャンド・ビー・ジャイン

アジット・ビー・サカー

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

ER Squibb and Sons LLC

Original Assignee

ER Squibb and Sons LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-07-10

Filing date

1990-07-10

Publication date

1999-10-18

1990-07-10 Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC

1991-03-01 Publication of JPH0348623A publication Critical patent/JPH0348623A/ja

1999-10-18 Application granted granted Critical

1999-10-18 Publication of JP2965633B2 publication Critical patent/JP2965633B2/ja

2014-10-18 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 title description 6
229960002490 fosinopril Drugs 0.000 title description 6
TVTJZMHAIQQZTL-WATAJHSMSA-M sodium;(2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylate Chemical compound [Na+].C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C([O-])=O)CCCC1=CC=CC=C1 TVTJZMHAIQQZTL-WATAJHSMSA-M 0.000 claims abstract description 39
229960001880 fosinopril sodium Drugs 0.000 claims abstract description 38
229940045902 sodium stearyl fumarate Drugs 0.000 claims abstract description 28
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims abstract description 27
239000007884 disintegrant Substances 0.000 claims abstract description 19
239000011230 binding agent Substances 0.000 claims abstract description 17
239000000945 filler Substances 0.000 claims abstract description 14
239000000314 lubricant Substances 0.000 claims abstract description 11
239000002934 diuretic Substances 0.000 claims abstract description 9
239000008172 hydrogenated vegetable oil Substances 0.000 claims abstract description 9
230000001882 diuretic effect Effects 0.000 claims abstract description 5
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 50
239000000203 mixture Substances 0.000 claims description 41
GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 36
239000008101 lactose Substances 0.000 claims description 33
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 26
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 26
229940069328 povidone Drugs 0.000 claims description 26
229960000913 crospovidone Drugs 0.000 claims description 22
229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 22
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 22
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 15
229940016286 microcrystalline cellulose Drugs 0.000 claims description 15
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 15
239000008108 microcrystalline cellulose Substances 0.000 claims description 15
JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 claims description 12
229960001523 chlortalidone Drugs 0.000 claims description 12
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 10
229960002003 hydrochlorothiazide Drugs 0.000 claims description 10
239000011734 sodium Substances 0.000 claims description 10
229910052708 sodium Inorganic materials 0.000 claims description 10
229920002785 Croscarmellose sodium Polymers 0.000 claims description 7
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 6
229920003133 pregelled starch Polymers 0.000 claims description 6
229920003109 sodium starch glycolate Polymers 0.000 claims description 6
239000008109 sodium starch glycolate Substances 0.000 claims description 6
229940079832 sodium starch glycolate Drugs 0.000 claims description 6
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 5
229920002472 Starch Polymers 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
229940032147 starch Drugs 0.000 claims description 4
239000008107 starch Substances 0.000 claims description 4
235000019698 starch Nutrition 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 6
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
239000000654 additive Substances 0.000 claims 2
230000000996 additive effect Effects 0.000 claims 2
229920000881 Modified starch Polymers 0.000 claims 1
239000004368 Modified starch Substances 0.000 claims 1
MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 claims 1
235000019426 modified starch Nutrition 0.000 claims 1
235000015424 sodium Nutrition 0.000 claims 1
229940071138 stearyl fumarate Drugs 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 abstract description 3
238000000034 method Methods 0.000 description 12
239000004615 ingredient Substances 0.000 description 10
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
239000002904 solvent Substances 0.000 description 5
-1 4-phenylbutyl Chemical group 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
229940030606 diuretics Drugs 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
238000009472 formulation Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000003086 colorant Substances 0.000 description 2
239000013020 final formulation Substances 0.000 description 2
229920001519 homopolymer Polymers 0.000 description 2
239000005022 packaging material Substances 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
238000003860 storage Methods 0.000 description 2
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
229960002576 amiloride Drugs 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229960003515 bendroflumethiazide Drugs 0.000 description 1
HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
239000013590 bulk material Substances 0.000 description 1
MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
229960004064 bumetanide Drugs 0.000 description 1
229960002155 chlorothiazide Drugs 0.000 description 1
238000004040 coloring Methods 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
239000011928 denatured alcohol Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
229960003199 etacrynic acid Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
RGUQWGXAYZNLMI-UHFFFAOYSA-N flumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O RGUQWGXAYZNLMI-UHFFFAOYSA-N 0.000 description 1
229960003028 flumethiazide Drugs 0.000 description 1
229960003883 furosemide Drugs 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 1
229960002429 proline Drugs 0.000 description 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
229960002256 spironolactone Drugs 0.000 description 1
239000003451 thiazide diuretic agent Substances 0.000 description 1
229960001288 triamterene Drugs 0.000 description 1
239000003039 volatile agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

JP2185179A 1989-07-10 1990-07-10 フォシノプリル錠剤 Expired - Lifetime JP2965633B2 (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US37768389A	1989-07-10	1989-07-10
US377,683		1989-07-10

Publications (2)

Publication Number	Publication Date
JPH0348623A JPH0348623A (ja)	1991-03-01
JP2965633B2 true JP2965633B2 (ja)	1999-10-18

Family

ID=23490122

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2185179A Expired - Lifetime JP2965633B2 (ja)	1989-07-10	1990-07-10	フォシノプリル錠剤

Country Status (8)

Country	Link
EP (1)	EP0408273B1 (fr)
JP (1)	JP2965633B2 (fr)
AT (1)	ATE100321T1 (fr)
CA (1)	CA2019324C (fr)
DD (1)	DD299154A5 (fr)
DE (1)	DE69006125T2 (fr)
DK (1)	DK0408273T3 (fr)
ES (1)	ES2062376T3 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5464632C1 (en) *	1991-07-22	2001-02-20	Prographarm Lab	Rapidly disintegratable multiparticular tablet
FR2679451B1 (fr) *	1991-07-22	1994-09-09	Prographarm Laboratoires	Comprime multiparticulaire a delitement rapide.
ES2059260B1 (es) *	1992-10-06	1995-04-16	Espanola Prod Quimicos	Procedimiento de preparacion de comprimidos conteniendo diclofenaco; dispersables en agua.
FR2766089B1 (fr) *	1997-07-21	2000-06-02	Prographarm Lab	Comprime multiparticulaire perfectionne a delitement rapide
FR2784895B1 (fr) *	1998-10-23	2004-12-17	Gattefosse Ets Sa	Comprime a croquer a gout masque et liberation immediate du principe actif et procede de fabrication
UA75569C2 (en) *	1998-12-01	2006-05-15	Reddys Lab Ltd Dr	Pharmaceutical composition of thiadiazolidinedione and method for its manufacture
CA2363053C (fr) *	2001-11-09	2011-01-25	Bernard Charles Sherman	Formulation pour pastilles de bisulfate de clopidogrel
KR20010114199A (ko) *	2001-12-11	2001-12-29	유형선	제약산업에서 사용될 수 있는 고형제제를 위한 직타용부형제의 새로운 의약품 조성물
US7198653B2 (en)	2003-07-31	2007-04-03	Delavau Llc	Calcium carbonate granulation
US20050095287A1 (en) *	2003-10-29	2005-05-05	Matharu Amol S.	Fosinopril composition
EP3165220B2 (fr) *	2004-12-03	2024-11-13	Merck Sharp & Dohme LLC	Composition pharmaceutique contenant un agent d'anti-nucléation
GR1006875B (el) *	2005-06-30	2010-07-12	"Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε.,	Βελτιωμενες φαρμακευτικες συνθεσεις περιεχουσες αναστολεις του μετατρεπτικου ενζυμου αγγειοτενσινης και μεθοδοι παρασκευης αυτων.
US9138414B1 (en)	2006-09-15	2015-09-22	Delavau Llc	Calcium supplement having enhanced absorption
SI23149A (sl)	2009-09-21	2011-03-31	Silverstone Pharma	Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
US10076494B2 (en)	2016-06-16	2018-09-18	Dexcel Pharma Technologies Ltd.	Stable orally disintegrating pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4217347A (en) *	1977-12-27	1980-08-12	E. R. Squibb & Sons, Inc.	Method of treating hypertension and medicaments therefor
US4384123A (en) *	1980-12-04	1983-05-17	E. R. Squibb & Sons, Inc.	Phosphinylalkanoyl substituted prolines
US4793998A (en) *	1986-10-20	1988-12-27	Warner-Lambert Company	Stabilized drug compositions
AU612137B2 (en) *	1987-04-27	1991-07-04	E.R. Squibb & Sons, Inc.	Method for inhibiting loss of cognitive functions employing an ace inhibitor

1990
- 1990-06-19 CA CA002019324A patent/CA2019324C/fr not_active Expired - Lifetime
- 1990-07-09 ES ES90307449T patent/ES2062376T3/es not_active Expired - Lifetime
- 1990-07-09 AT AT90307449T patent/ATE100321T1/de not_active IP Right Cessation
- 1990-07-09 EP EP90307449A patent/EP0408273B1/fr not_active Expired - Lifetime
- 1990-07-09 DE DE69006125T patent/DE69006125T2/de not_active Expired - Lifetime
- 1990-07-09 DK DK90307449.0T patent/DK0408273T3/da active
- 1990-07-10 JP JP2185179A patent/JP2965633B2/ja not_active Expired - Lifetime
- 1990-10-01 DD DD90344330A patent/DD299154A5/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
ATE100321T1 (de)	1994-02-15
EP0408273B1 (fr)	1994-01-19
ES2062376T3 (es)	1994-12-16
DK0408273T3 (da)	1994-02-28
EP0408273A1 (fr)	1991-01-16
CA2019324C (fr)	1996-08-20
DE69006125D1 (de)	1994-03-03
DE69006125T2 (de)	1994-05-19
JPH0348623A (ja)	1991-03-01
DD299154A5 (de)	1992-04-02
CA2019324A1 (fr)	1991-01-10

Legal Events

Date	Code	Title	Description
2004-08-03	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2005-08-02	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2006-08-08	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2007-08-07	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20080813 Year of fee payment: 9
2008-07-31	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20080813 Year of fee payment: 9
2008-08-05	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20090813 Year of fee payment: 10
2009-07-30	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20090813 Year of fee payment: 10
2009-08-04	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20100813 Year of fee payment: 11
2010-07-10	EXPY	Cancellation because of completion of term

Publication	Publication Date	Title
US5006344A (en)	1991-04-09	Fosinopril tablet formulations
RU2252751C2 (ru)	2005-05-27	Таблетка с немедленным высвобождением
KR860000840B1 (ko)	1986-07-09	지속성 매트릭스 정제조성물의 제조방법
EP0408273B1 (fr)	1994-01-19	Formulations des comprimés contenant du fosinopril
HU229134B1 (en)	2013-08-28	Process of forming a compressed solid oral dosage form comprising valsartan
EP0365480A1 (fr)	1990-04-25	Composition à disperser
US5004651A (en)	1991-04-02	Stabilizing system for solid dosage forms
EP0441245B1 (fr)	1994-09-14	Procédé de préparation de comprimés médicamenteux à libération retardée
US5198228A (en)	1993-03-30	Direct dry compressible acetaminophen tablet
US3332848A (en)	1967-07-25	Microcrystalline cellulose with starch in niacinamide ascorbic acid tablet granulations
US5037658A (en)	1991-08-06	Direct dry compressible acetaminophen composition
SG172136A1 (en)	2011-07-28	A disintegrating tablet
JP5524435B2 (ja)	2014-06-18	新規医薬組成物及びその調製のための方法
US5130140A (en)	1992-07-14	Method of making direct dry compressible acetaminophen composition
AU776522B2 (en)	2004-09-16	Fosinopril sodium tablet formulation
US5512298A (en)	1996-04-30	Cytarabine ocfosfate hard capsule
KR100571614B1 (ko)	2006-04-17	속용성 의약 조성물
CA1209046A (fr)	1986-08-05	Composes diuretiques/antihypertenseurs et methode de preparation
US6737419B2 (en)	2004-05-18	Benazepril hydrochloride tablet formulations
EP0950419B1 (fr)	2003-07-02	Une préparation solide et sa méthode de production
JPH02131434A (ja)	1990-05-21	薬剤組成物
JP3232687B2 (ja)	2001-11-26	イミダプリル含有製剤
JPH0291018A (ja)	1990-03-30	湿気に対して安定な固形バルプロ酸製剤とその製造法
CA2442898A1 (fr)	2005-03-26	Formulation pour comprimes de fosinopril sodique
HK1035486B (en)	2005-05-27	Immediate release oral formulation comprising peptide thrombin inhibitors and a combination of microcrystalline cellulose and sodium starch glycollate